Cognitive Decline in AD

A Cohort Study of Cognitive Decline in Alzheimer Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03946930

Enrollment

500

Registered

2019-05-13

Start date

2018-12-13

Completion date

2027-12-31

Last updated

2024-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease

Brief summary

There is lack of information on the risk factors of accelerated cognitive decline in older people with Alzheimer disease (AD). The extent of neurodegeneration and white matter disease has been reported to be important factors. In addition there may be biomarkers e.g. inflammatory cytokines that can contribute to cognitive decline. The impact of care arrangement and physical activity may also be important. Insulin signaling is impaired in Alzheimer disease (AD). We therefore propose to perform a cohort study of older people with AD. This will be based on an on-going AD registry which was designed to identify genetic biomarkers for AD. Detailed neurocognitive tests and lifestyle information are available. In addition, volumetric MRI brain scans were performed in all AD subjects. The hypothesis is that MRI brain volumes, serum biomarkers, physical activity, physical functioning are independently associated with cognitive decline in older people with AD. The objective is to identify risk factors of accelerated cognitive decline so that preventive measures can be designed to delay dependency in AD.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

65 Years to 92 Years

Healthy volunteers

Inclusion criteria

* Sufficient Cantonese competency for cognitive test * Clinical diagnosis of AD * FAST test staging 3-5

Exclusion criteria

* Subjects who refuse blood taking procedure * No reliable family caregiver informant (person contact at least once a month)

Design outcomes

Primary

Measure	Time frame	Description
Alzheimer's Disease Assessment Scale-cognitive subscale ADAS-COG	24-Months	Cognitive assessment for dementia

Countries

Hong Kong

Contacts

Primary ContactTimothy Kwok, MD

tkwok@cuhk.edu.hk+852 35053145

Backup ContactHazel Mok, BSc

hazelmok@cuhk.edu.hk+852 35053990

Outcome results